Your browser doesn't support javascript.
loading
Transcription factor 4 expression in circulating tumor cells from castration-resistant prostate cancer.
Nagaya, Naoya; Lee, Geun Taek; Lu, Yan; Ashizawa, Takeshi; Nagata, Masayoshi; Kim, Isaac Yi; Horie, Shigeo.
Afiliación
  • Nagaya N; Department of Urology Juntendo University Graduate School of Medicine Tokyo Japan.
  • Lee GT; Section of Urologic Oncology Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA.
  • Lu Y; Section of Urologic Oncology Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA.
  • Ashizawa T; Department of Urology Juntendo University Graduate School of Medicine Tokyo Japan.
  • Nagata M; Department of Urology Juntendo University Graduate School of Medicine Tokyo Japan.
  • Kim IY; Department of Urology Juntendo University Graduate School of Medicine Tokyo Japan.
  • Horie S; Section of Urologic Oncology Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA.
IJU Case Rep ; 4(3): 159-162, 2021 May.
Article en En | MEDLINE | ID: mdl-33977248
INTRODUCTION: Neuroendocrine differentiation is partly caused by antiandrogen therapy and exhibits an androgen receptor-independent growth mechanism. We hypothesized that the expression of transcription factor 4, an inducer of neuroendocrine differentiation, in circulating tumor cells is related to drug resistance in castration-resistant prostate cancer. CASE PRESENTATION: We evaluate the messenger ribonucleic acid expression of transcription factor 4 in circulating tumor cells from 17 patients with castration-resistant prostate cancer and compared these levels between patients receiving antiandrogen therapies and those who were resistant to antiandrogen therapies and receiving chemotherapies. The expression of transcription factor 4 in circulating tumor cells was significantly higher among patients receiving chemotherapies. CONCLUSION: This study shows that transcription factor 4 is higher in the group of patients who were judged by their physicians to need chemotherapy treatment.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IJU Case Rep Año: 2021 Tipo del documento: Article Pais de publicación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IJU Case Rep Año: 2021 Tipo del documento: Article Pais de publicación: Australia